On the mechanism of the inhibition of glycolysis by glyceraldehyde

L-Glyceraldehyde Inhibits Neuroblastoma Cell Growth via a Multi-Modal Mechanism on Metabolism and Signaling

Glyceraldehyde (GA) is a three-carbon monosaccharide that can be present in cells as a by-product of fructose metabolism. Bruno Mendel and Otto Warburg showed that the application of GA to cancer cells inhibits glycolysis and their growth. However, the molecular mechanism by which this occurred was not clarified. We describe a novel multi-modal mechanism by which the L-isomer of GA (L-GA) inhibits neuroblastoma cell growth. L-GA induces significant changes in the metabolic profile, promotes oxidative stress and hinders nucleotide biosynthesis. GC-MS and 13C-labeling was employed to measure the flow of carbon through glycolytic intermediates under L-GA treatment. It was found that L-GA is a potent inhibitor of glycolysis due to its proposed targeting of NAD(H)-dependent reactions. This results in growth inhibition, apoptosis and a redox crisis in neuroblastoma cells. It was confirmed that the redox mechanisms were modulated via L-GA by proteomic analysis. Analysis of nucleotide pools in L-GA-treated cells depicted a previously unreported observation, in which nucleotide biosynthesis is significantly inhibited. The inhibitory action of L-GA was partially relieved with the co-application of the antioxidant N-acetyl-cysteine. We present novel evidence for a simple sugar that inhibits cancer cell proliferation via dysregulating its fragile homeostatic environment.

A strategic tool to improve the study of molecular determinants of Alzheimer's disease: The role of glyceraldehyde

Alzheimer's disease (AD) is the most prevalent form of dementia and is characterized by progressive neurodegeneration leading to severe cognitive, memory, and behavioral impairments. The onset of AD involves a complex interplay among various factors, including age, genetics, chronic inflammation, and impaired energy metabolism. Despite significant efforts, there are currently no effective therapies capable of modifying the course of AD, likely owing to an excessive focus on the amyloid hypothesis and a limited consideration of other intracellular pathways. In the present review, we emphasize the emerging concept of AD as a metabolic disease, where alterations in energy metabolism play a critical role in its development and progression. Notably, glucose metabolism impairment is associated with mitochondrial dysfunction, oxidative stress, Ca2+ dyshomeostasis, and protein misfolding, forming interconnected processes that perpetuate a detrimental self-feeding loop sustaining AD progression. Advanced glycation end products (AGEs), neurotoxic compounds that accumulate in AD, are considered an important consequence of glucose metabolism disruption, and glyceraldehyde (GA), a glycolytic intermediate, is a key contributor to AGEs formation in both neurons and astrocytes. Exploring the impact of GA-induced glucose metabolism impairment opens up exciting possibilities for creating an easy-to-handle in vitro model that recapitulates the early stage of the disease. This model holds great potential for advancing the development of novel therapeutics targeting various intracellular pathways implicated in AD pathogenesis. In conclusion, looking beyond the conventional amyloid hypothesis could lead researchers to discover promising targets for intervention, offering the possibility of addressing the existing medical gaps in AD treatment.

Glyceraldehyde caused Alzheimer's disease-like alterations in diagnostic marker levels in SH-SY5Y human neuroblastoma cells

Clinical evidence has implicated diabetes mellitus as one of the risk factors for the development and progression of Alzheimer’s disease (AD). However, the neurotoxic pathway activated due to abnormalities in glucose metabolism has not yet been identified in AD. In order to investigate the relationship between impaired cerebral glucose metabolism and the pathophysiology of AD, SH-SY5Y human neuroblastoma cells were exposed to glyceraldehyde (GA), an inhibitor of glycolysis. GA induced the production of GA-derived advanced glycation end-products (GA-AGEs) and cell apoptosis, glycolytic inhibition, decreases in the medium concentrations of diagnostic markers of AD, such as amyloid β 1-42 (Aβ42), and increases in tau phosphorylation. These results suggest that the production of GA-AGEs and/or inhibition of glycolysis induce AD-like alterations, and this model may be useful for examining the pathophysiology of AD.

Basis for the mutational acquisition of the ability of Aerobacter aerogenes to grow on L-mannose

Growth of Aerobacter aerogenes PRL-R3 on the unnatural hexose l-mannose as a sole carbon source is dependent upon the selection of a mutant. Growth of the mutant on l-mannose did not require the synthesis of novel enzymes for the degradation of l-mannose, since enzymes of the l-rhamnose degradative pathway could serve this function. However, unlike most other apparent gain mutations that have been described, the mutant was not constitutive for the degradative enzymes; isomerase, kinase, and aldolase activities functional in the degradation of both l-mannose and l-rhamnose were induced by either of these hexoses in the wild type as well as in the mutant. The fact that the wild type could metabolize l-mannose also ruled out the possibility that the cells were not permeable to l-mannose. Growth of the wild type on nutrient broth was severely inhibited by l-mannose coincident with the onset of l-mannose metabolism. A similar inhibition of growth of the mutant was overcome in about 2 hr. Both strains utilized l-rhamnose and l-mannose sequentially in a mineral medium containing both of these hexoses; at the onset of l-mannose metabolism, growth of the wild type, but not of the mutant, was inhibited. Thus, wild-type A. aerogenes cannot grow on l-mannose because of the toxicity of l-mannose or its metabolites. A mutation which overcomes the toxicity enables the organism to utilize l-mannose as a sole source of carbon and energy for growth.

The metabolism of D-glyceraldehyde by the lens

1. The metabolism of d-glyceraldehyde by the lens was examined. 2. When low concentrations of d-[U-(14)C]glyceraldehyde were incubated with lens extracts there was no incorporation of the label into protein; more than two-thirds of the labelled metabolites consisted of glyceric acid and glycerol, their relative proportions depending on the species. Lactic acid, a phosphate, glutathione-glyceraldehyde compounds and a neutral compound were also formed. 3. When high concentrations of d-[U-(14)C]glyceraldehyde were incubated with lens, extensive incorporation of the label into protein occurred and the protein became yellow-brown. This coloured protein did not exhibit the fluorescent properties shown by the brown proteins of human cataractous senile lens, or of naphthaquinone-treated lens. 4. Evidence that d-glyceraldehyde is formed by the lens was sought but not found.